Impact of Protein Stability, Cellular Localization, and Abundance on Proteomic Detection of Tumor-Derived Proteins in Plasma

Tumor-derived, circulating proteins are potentially useful as biomarkers for detection of cancer, for monitoring of disease progression, regression and recurrence, and for assessment of therapeutic response. Here we interrogated how a protein's stability, cellular localization, and abundance affect its observability in blood by mass-spectrometry-based proteomics techniques. We performed proteomic profiling on tumors and plasma from two different xenograft mouse models. A statistical analysis of this data revealed protein properties indicative of the detection level in plasma. Though 20% of the proteins identified in plasma were tumor-derived, only 5% of the proteins observed in the tumor tissue were found in plasma. Both intracellular and extracellular tumor proteins were observed in plasma; however, after normalizing for tumor abundance, extracellular proteins were seven times more likely to be detected. Although proteins that were more abundant in the tumor were also more likely to be observed in plasma, the relationship was nonlinear: Doubling the spectral count increased detection rate by only 50%. Many secreted proteins, even those with relatively low spectral count, were observed in plasma, but few low abundance intracellular proteins were observed. Proteins predicted to be stable by dipeptide composition were significantly more likely to be identified in plasma than less stable proteins. The number of tryptic peptides in a protein was not significantly related to the chance of a protein being observed in plasma. Quantitative comparison of large versus small tumors revealed that the abundance of proteins in plasma as measured by spectral count was associated with the tumor size, but the relationship was not one-to-one; a 3-fold decrease in tumor size resulted in a 16-fold decrease in protein abundance in plasma. This study provides quantitative support for a tumor-derived marker prioritization strategy that favors secreted and stable proteins over all but the most abundant intracellular proteins.

[1]  David C Muddiman,et al.  Mass spectrometry-based biomarker discovery: toward a global proteome index of individuality. , 2009, Annual review of analytical chemistry.

[2]  Damon H. May,et al.  Brain-specific Proteins Decline in the Cerebrospinal Fluid of Humans with Huntington Disease , 2009, Molecular & Cellular Proteomics.

[3]  Hye-Jin Sung,et al.  Proteomic approaches in lung cancer biomarker development , 2009, Expert review of proteomics.

[4]  Ruedi Aebersold,et al.  Targeted proteomic strategy for clinical biomarker discovery , 2009, Molecular oncology.

[5]  Sanjiv S Gambhir,et al.  Cancer Screening: A Mathematical Model Relating Secreted Blood Biomarker Levels to Tumor Sizes , 2008, PLoS medicine.

[6]  Michelle A. Anderson,et al.  A Mouse to Human Search for Plasma Proteome Changes Associated with Pancreatic Tumor Development , 2008, PLoS medicine.

[7]  S. Hanash,et al.  Mining the plasma proteome for cancer biomarkers , 2008, Nature.

[8]  S. Hanash,et al.  Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells. , 2008, Journal of proteome research.

[9]  Heidi Zhang,et al.  Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. , 2007, Journal of proteome research.

[10]  Veronika A. Glukhova,et al.  Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. , 2007, Journal of proteome research.

[11]  D. T. Wong,et al.  Human body fluid proteome analysis , 2006, Proteomics.

[12]  Veronika A. Glukhova,et al.  Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS. , 2006, Journal of proteome research.

[13]  David J. States,et al.  Erratum: Computational Proteomics Analysis System (CPAS): An extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments (Journal of Proteome Research (2006) 5 (112-121)) , 2006 .

[14]  N. Anderson,et al.  A List of Candidate Cancer Biomarkers for Targeted Proteomics , 2006, Biomarker insights.

[15]  K. Resing,et al.  Comparison of Label-free Methods for Quantifying Human Proteins by Shotgun Proteomics*S , 2005, Molecular & Cellular Proteomics.

[16]  David E. Misek,et al.  Intact-protein-based High-resolution Three-dimensional Quantitative Analysis System for Proteome Profiling of Biological Fluids* , 2005, Molecular & Cellular Proteomics.

[17]  S. Hanash,et al.  Profiling of the cell surface proteome , 2003, Proteomics.

[18]  R. Aebersold,et al.  A statistical model for identifying proteins by tandem mass spectrometry. , 2003, Analytical chemistry.

[19]  David E. Misek,et al.  Profiling of pathway-specific changes in gene expression following growth of human cancer cell lines transplanted into mice , 2003, Genome Biology.

[20]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[21]  Alexey I Nesvizhskii,et al.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. , 2002, Analytical chemistry.

[22]  Margaret Sullivan Pepe,et al.  Combining Several Screening Tests: Optimality of the Risk Score , 2002, Biometrics.

[23]  M. W. Pandit,et al.  Correlation between stability of a protein and its dipeptide composition: a novel approach for predicting in vivo stability of a protein from its primary sequence. , 1990, Protein engineering.

[24]  Adam Rauch,et al.  Computational Proteomics Analysis System (CPAS): an extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments. , 2006, Journal of proteome research.